(cemiplimab-rwlc) Archives - tgiHealthCareerp

FDA Approves Libtayo (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-Small Cell Lung Cancer with PD-L1 Expression of ≥50%

02/22/2021 (cemiplimab-rwlc), ≥50%, advanced, Approves, cancer, Cell, expression, FDA, First-line, for, Libtayo, lung, Monotherapy, Non-Small, of, Patients, PD-L1, with

TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration